comparemela.com

Latest Breaking News On - Prnewswire biocytogen - Page 1 : comparemela.com

Biocytogen Subsidiary Eucure Biopharma Completes First Patient Dosing for Phase I Clinical Trial of YH003 (Anti-CD40 mAb) Triple Combination Therapy

BEIJING, April 6, 2022 /PRNewswire/ Biocytogen subsidiary Eucure Biopharma announced the first patient dosing for a phase I clinical trial (No..

Biocytogen Announces Collaboration With Envigo To Distribute the B-NDG Triple Immunodeficient and Humanizable Mouse Model

Biocytogen Announces Collaboration With Envigo To Distribute the B-NDG Triple Immunodeficient and Humanizable Mouse Model
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Biocytogen announces acquisition of a third Beacon Optofluidic system [ ]

25 febbraio 2021 16:47 Fonte: Adnkronos #salute-e-benessere BOSTON, Feb. 25, 2021 /PRNewswire/ Biocytogen, a company dedicated to accelerating therapeutic antibody discovery, has announced the acquisition of a third Beacon Optofluidic system. The new instrument, developed by Berkeley Lights, will support the expansion of Biocytogen s antibody discovery service platform in the greater Boston area for collaborations across the globe. Founded on its successful gene editing platform, Biocytogen recently developed humanized immunoglobulin mice that carry the full variable region repertoire (RenMab™), as well as a related common light chain strain, RenLite™. Generation of fully human antibodies in these models minimizes the time required to develop high-affinity antibody therapeutics with favorable pharmacokinetic properties. Biocytogen s integrative use of Berkeley Lights industry-leading light-sorting technology further accelerates the process, due to the rapid screening of t

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.